Hormonal
GLP-1/GIP/Glucagon triple-agonists (e.g., Retatrutide) produce superior weight loss (up to 24.2%) compared to dual-agonists and GLP-1 monotherapies by simultaneously reducing food intake and increasing energy expenditure.
Retatrutide is a once-weekly injection that targets three hormones (GLP-1, GIP, Glucagon) to maximize weight loss. In clinical trials, doses up to 12mg resulted in an average 24.2% body weight loss over 48 weeks, outperforming single-hormone drugs. While it causes mild gastrointestinal side effects, the significant weight reduction makes it a highly effective option for obesity management.
A dose of 1 to 8 mg once weekly was given for 48 weeks... The mean percentage weight reduction in the retatrutide groups at 48 weeks were 8.7%, 17.1%, 22.8%, and 24.2% for the groups treated with 1 mg, combined 4 mg, combined 8, and 12 mg, respectively.
Why this rating
Based on Phase 2 RCTs (LY3437943) with clear dose-response data, though Phase 3 results are noted as ongoing.
Source
Innovative Glucagon-based Therapies for Obesity
Kibret Enyew Belay et al. · Journal of the Endocrine Society · 2024
DOI 10.1210/jendso/bvae197
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →